Madrigal Pharmaceuticals, Inc. Investigation - MDGL

Company
Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL)

Learn more about the Madrigal Pharmaceuticals, Inc. Investigation

Required Field

Required Field

Required Field

  • $1 - $1,000
  • $1001 - $10,000
  • $10,001 - $25,000
  • $25,001 - $50,000
  • $50,001 - $100,000
  • $100,001 - $250,000
  • $250,001 - $500,000
  • $500,000+

There is no cost or obligation for you to submit.

The submission of this form does not create an attorney-client relationship.

Please Upload related files below

Add Transactions

Purchases

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Purchases

Sales

1.
  • Common Stock
  • Preferred Stock
  • Bonds
  • Calls
  • Puts
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12

Additional Sales

Please input at least 1 transaction or press "skip for now" button below

Please fill in all the fields for your transaction or press "skip for now" button below

Alternatively, you may upload your transactions below or e-mail them to [email protected]

Upload Your Stock Tickers

Tell us the stocks you own using SnapTrade, and we will keep you informed about class action litigation related to your stocks. We monitor critical case developments that may affect the price of your shares and your possible monetary recovery. SnapTrade only shares the tickers you own and your transaction history, not your account numbers. Using SnapTrade and participating in our monitoring service is free and does not create any attorney-client relationship or obligation on your part.

Don’t miss out on possible monetary recovery - link your brokerage account with SnapTrade.

Skip

Madrigal Pharmaceuticals, Inc. Investigation Details

Levi & Korsinsky is investigating whether Madrigal Pharmaceuticals, Inc. (NASDAQ: MDGL) may have violated federal securities laws in connection with statements made to investors before November 3, 2026. On that date, Madrigal reported in its quarterly report on Form 10-Q that Dr. Michael Charlton, its former Senior Vice President, Head of Clinical Development, had filed a whistleblower complaint on October 9, 2026 describing the suppression of adverse liver-injury data, efficacy results that could not be reconciled with the Company's own source data, and an unblinded Board member controlling the adjudication of clinical outcomes. Madrigal shares fell $34.84, or 8.1%, to close at $396.32 that day. Shareholders who lost money on MDGL are encouraged to submit their information for a no-cost, no-obligation review of their potential recovery.

Get Started